Siegel RL, Giaquinto AN, Jemal A. (2024) Cancer statistics, 2024. CA: Cancer J Clinicians. 2024;74(1):12–49.

Google Scholar 

Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA: Cancer J Clinicians. 2010;60(5):277–300.

Google Scholar 

Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules. 2022;27(17).

Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment. Am Soc Clin Oncol Educ Book. 2023;43:e390166.

Article  PubMed  Google Scholar 

Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2024;27(2):327–33.

Article  CAS  PubMed  Google Scholar 

Smith CEP, Prasad V. Targeted Cancer Therapies. Am Fam Physician. 2021;103(3):155–63.

PubMed  Google Scholar 

Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. (2023) Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(10):1067–96.

Article  CAS  PubMed  Google Scholar 

Taylor AK, Kosoff D, Emamekhoo H, Lang JM, Kyriakopoulos CE. PARP inhibitors in metastatic prostate cancer. Front Oncol. 2023;13:1159557.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bakht MK, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699–715.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hawkey NM, Sartor AO, Morris MJ, Armstrong AJ. Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. Clin Adv Hematol Oncol. 2022;20(4):227–38.

PubMed  PubMed Central  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, et al. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. NPJ Precis Oncol. 2024;8(1):104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang J, Chadha JS. Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies. Cancers (Basel). 2024;16(17).

Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181–200.

Article  PubMed  PubMed Central  Google Scholar 

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015;60(4):547–60.

Article  CAS  PubMed  Google Scholar 

FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer [press release]. FDA.gov, 5/20/20 2020.

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091–102.

Article  PubMed  Google Scholar 

Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, et al. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023;84(3):321–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer. N Engl J Med. 2023;388(8):719–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fallah J, Xu J, Weinstock C, Brave MH, Bloomquist E, Fiero MH, et al. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With <i>BRCA</i>-Mutated Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2024;42(5):605–13.

Article  CAS  PubMed  Google Scholar 

Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evidence. 2022;1(9):EVIDoa2200043.

Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291–303.

Article  CAS  PubMed  Google Scholar 

Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023;41(18):3339–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3(11):1245–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pilié PG, Gay CM, Byers LA, O’Connor MJ, Yap TA. PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clin Cancer Res. 2019;25(13):3759–71.

Article  PubMed  Google Scholar 

Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(10):1094–108.

Article  CAS  PubMed  Google Scholar 

Agarwal N, Azad A, Carles J, Fay AP, Matsubara N, Szczylik C, et al. Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. J Clin Oncol. 2025;43(5_suppl):LBA18-LBA.

Agarwal N, Azad A, Fizazi K, Mateo J, Matsubara N, Shore ND, et al. Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC). Journal of Clinical Oncology. 2022;40(6_suppl):TPS221-TPS.

Rathkopf DE, Chi KN, Olmos D, Cheng HH, Agarwal N, Graff JN, et al. AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). J Clin Oncol. 2021;39(6_suppl):TPS176-TPS.

Pommier Y, O’Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362):362ps17.

Article  PubMed  Google Scholar 

Herencia-Ropero A, Llop-Guevara A, Staniszewska AD, Domènech-Vivó J, García-Galea E, Moles-Fernández A, et al. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models. Genome Med. 2024;16(1):107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yap T, Im S-A, Schram A, Sharp A, Balmana J, Baird R, editors. First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations. Cancer Research; 2022.

Azad A, Voskoboynik M, Joshua AM, Weickhardt AJ, Sankey P, Pacey S, et al. PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results. J Clin Oncol. 2024;42(4_suppl):123-.

Chi KN, Agarwal N, Armstrong AJ, Hellmis E, Schlürmann F, Sugimoto M, et al. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). J Clin Oncol. 2024;42(16_suppl):TPS5123-TPS.

Mei L, Zhang J, He K, Zhang J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol. 2019;12(1):43.

Article  PubMed  PubMed Central  Google Scholar 

Cui Y, Palii SS, Innes CL, Paules RS. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents. Cell Cycle. 2014;13(22):3541–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reichert ZR, Devitt ME, Alumkal JJ, Smith DC, Caram MV, Palmbos P, et al. Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial). J Clin Oncol. 2022;40(6_suppl):88-.

Tang Z, Pilié PG, Geng C, Manyam GC, Yang G, Park S, et al. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer. Clin Cancer Res. 2021;27(17):4898–909.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437–47.